Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer, targeting tumor cells that rely on topoisomerase I activity.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use, including both private and public health systems.

Irinotecan is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine therapy. Advanced colorectal cancer: reduces tumor burden in patients with disease progression. Colorectal cancer (adjuvant setting): investigated in clinical trials for high‑risk patients.

Irinotecan may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss that is usually reversible. - Fatigue: generalized tiredness during treatment. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: intense inflammation of the colon. - Cholinergic syndrome: abdominal cramps, sweating, and bradycardia. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Pulmonary toxicity: rare lung inflammation.

Before initiating Irinotecan therapy, clinicians should assess patient-specific factors. - Hepatic function: adjust dose in patients with liver impairment. - Blood counts: monitor complete blood count regularly for neutropenia. - Hydration: ensure adequate fluid intake to mitigate severe diarrhea. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that may increase exposure. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise SN‑38 levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other myelosuppressive agents: additive bone‑marrow suppression. - Fluoroquinolones: potential for enhanced neutropenia. - Loperamide: may mask early signs of severe diarrhea.